We are looking for patients with moderate to severe asthma for a new clinical study!

Do you have moderate to severe asthma?

About moderate to severe asthma

Moderate to severe asthma is a common inflammatory disease that affects the airways and lungs. Inflammation and constriction of the airways in the lungs can lead to limitations in daily activities, reduced quality of life, emergency department visits, hospitalizations, and even death. Asthma can cause shortness of breath, wheezing, coughing, and difficulty sleeping. Asthma is a chronic disease that affects up to 262 million people worldwide. There are a variety of treatments to relieve symptoms

What is the AIRCULES study?

Researchers at selected research centers are looking for people aged 18 to 80 years who have been diagnosed with moderate to severe asthma within the past 12 months. The goal of the AIRCULES study is to learn more about the investigational drug Lunsekimig and whether it can improve symptoms in people with moderate to severe asthma, as well as its associated safety and tolerability. The investigational drug Lunsekimig is given as an injection under the skin (also called a subcutaneous injection) and is investigational, which means it has not been fully tested and has not been approved by any health authorities, except for use in clinical studies like this one. Investigational drugs have not been approved by health authorities, such as the U.S. Food and Drug Administration (FDA), and are still being studied for treating asthma, so their effectiveness and safety have not yet been established.

This study is a randomized study, which means that participants are randomly assigned (like a coin flip) to one of two groups. One group takes the study drug Lunsekimig and the other takes a placebo. The placebo looks like the study drug but does not contain any active ingredients. This study is double-blind, so neither the participants nor the study doctor know which group you are in. The study doctor and study center staff follow both groups equally

This is a Phase 2 clinical study, and you will receive a subcutaneous injection of the study drug or placebo at specific time points. After an initial screening period of up to 4 weeks, you will receive the study drug Lunsekimig or placebo and your usual care for up to 48 weeks. Follow-up will be conducted for approximately 8 weeks after the last dose of study drug or placebo. Eligible participants will receive study drug or placebo, laboratory tests, and study-related medical care at no charge. If you choose to participate in the study, you may be compensated for your time and travel expenses for study visits.

Who can participate?

1. Aged 18-80 years

2. Diagnosed with asthma for 6 months and older

3. Currently treated with inhaled corticosteroids and 1-2 other controller medications

4. Have had an asthma attack or exacerbation in the past 12 months that required steroids (oral, intravenous, or intramuscular), regardless of whether emergency care or hospitalization was required

Common Questions

What is a clinical study?

Clinical studies explore whether experimental drugs, treatments, or devices are safe and effective in humans.

Clinical research is a scientific study that tests experimental drugs and treatments to determine if they are safe and effective. This is one of the most important steps in bringing new potential treatments to patients.

What is a "placebo"?

"Placebo" is a term used to describe a substance that looks like a study drug but does not contain any active ingredients.

Where can I find more information about this study?

Youcan learn more about this study at https://clinicaltrials.gov/study/NCT06102005?cond=NCT06102005&rank=1

We have hope that we can solve the long-standing problems of asthma.